Børresen-Dale AL - Search Results

1

Molecular portraits of human breast tumours.

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Perou CM, et al. Nature. 2000 Aug 17;406(6797):747-52. doi: 10.1038/35021093. Nature. 2000. PMID: 10963602

2

Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families.

Zelada-Hedman M, Børresen-Dale AL, Claro A, Chen J, Skoog L, Lindblom A. Zelada-Hedman M, et al. Br J Cancer. 1997;75(8):1201-4. doi: 10.1038/bjc.1997.205. Br J Cancer. 1997. PMID: 9099970 Free PMC article.

3

Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome.

Aas T, Geisler S, Paulsen T, Børresen-Dale AL, Varhaug JE, Lønning PE, Akslen LA. Aas T, et al. Acta Oncol. 1996;35 Suppl 5:5-8. doi: 10.3109/02841869609083960. Acta Oncol. 1996. PMID: 9142957

4

Absence of p21 expression is associated with abnormal p53 in human breast carcinomas.

Ellis PA, Lonning PE, Borresen-Dale A, Aas T, Geisler S, Akslen LA, Salter I, Smith IE, Dowsett M. Ellis PA, et al. Br J Cancer. 1997;76(4):480-5. doi: 10.1038/bjc.1997.413. Br J Cancer. 1997. PMID: 9275025 Free PMC article.

5

Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening.

Andersen TI, Eiken HG, Couch F, Kaada G, Skrede M, Johnsen H, Aloysius TA, Tveit KM, Tranebjaerg L, Dørum A, Møller P, Weber BL, Børresen-Dale AL. Andersen TI, et al. Hum Mutat. 1998;11(2):166-74. doi: 10.1002/(SICI)1098-1004(1998)11:2<166::AID-HUMU10>3.0.CO;2-X. Hum Mutat. 1998. PMID: 9482581

6

Mutation screening of BRCA1 using PTT and LOH analysis at 17q21 in breast carcinomas from familial and non-familial cases.

Sørlie T, Andersen TI, Bukholm I, Børresen-Dale AL. Sørlie T, et al. Breast Cancer Res Treat. 1998 Apr;48(3):259-64. doi: 10.1023/a:1005953519972. Breast Cancer Res Treat. 1998. PMID: 9598872

7

Analysis of p53, p16MTS, p21WAF1 and H-ras in archived bladder tumours from workers exposed to aromatic amines.

Sørlie T, Martel-Planche G, Hainaut P, Lewalter J, Holm R, Børresen-Dale AL, Montesano R. Sørlie T, et al. Br J Cancer. 1998 May;77(10):1573-9. doi: 10.1038/bjc.1998.259. Br J Cancer. 1998. PMID: 9635831 Free PMC article.

8

The APC gene I1307K variant is rare in Norwegian patients with familial and sporadic colorectal or breast cancer.

Lothe RA, Hektoen M, Johnsen H, Meling GI, Andersen TI, Rognum TO, Lindblom A, Børresen-Dale AL. Lothe RA, et al. Cancer Res. 1998 Jul 15;58(14):2923-4. Cancer Res. 1998. PMID: 9679946

9

p53 polymorphism and risk of cervical cancer.

Helland A, Langerød A, Johnsen H, Olsen AO, Skovlund E, Børresen-Dale AL. Helland A, et al. Nature. 1998 Dec 10;396(6711):530-1; author reply 532. doi: 10.1038/25034. Nature. 1998. PMID: 9859987 No abstract available.

10

CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1.

Nedelcheva Kristensen V, Haraldsen EK, Anderson KB, Lønning PE, Erikstein B, Kåresen R, Gabrielsen OS, Børresen-Dale AL. Nedelcheva Kristensen V, et al. Cancer Res. 1999 Jun 15;59(12):2825-8. Cancer Res. 1999. PMID: 10383140

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

507 results

Search Page